XML 25 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Earnings per Share | 9 Months Ended
--- | ---
Nov. 03, 2018
Earnings Per Share [Abstract] |
Earnings per Share | 6. Earnings per Share The following table provides a reconciliation of the number of shares outstanding for basic and diluted earnings per share:
|  | For the three months ended |  |  | For the nine months ended |
|  | November 3, 2018 |  |  | October 28, 2017 |  |  | November 3, 2018 |  |  | October 28, 2017 |
(in thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic weighted average common shares outstanding |  |  | 49,352 |  |  |  | 48,607 |  |  |  | 49,068 |  |  |  | 48,966 |
Common stock equivalents – stock options and restricted stock (1) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Diluted weighted average common shares outstanding |  |  | 49,352 |  |  |  | 48,607 |  |  |  | 49,068 |  |  |  | 48,966 |
| (1) | Common stock equivalents of 581 shares and 92 shares for the three months ended November 3, 2018 and October 28, 2017, respectively, and 494 shares and 67 shares for the nine months ended November 3, 2018 and October 28, 2017, respectively, were excluded due to the net loss.
The following potential common stock equivalents were excluded from the computation of diluted earnings per share in each period because the exercise price of such options was greater than the average market price per share of common stock for the respective periods or because of the unearned compensation associated with either stock options, restricted stock units, restricted or deferred stock had an anti-dilutive effect.
|  | For the three months ended |  |  | For the nine months ended |
|  | November 3, 2018 |  |  | October 28, 2017 |  |  | November 3, 2018 |  |  | October 28, 2017 |
(in thousands, except exercise prices) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 963 |  |  |  | 1,295 |  |  |  | 963 |  |  |  | 1,295 |
Restricted stock units |  |  | 754 |  |  |  | 1,106 |  |  |  | 786 |  |  |  | 1,109 |
Restricted and deferred stock |  |  | 24 |  |  |  | 54 |  |  |  | 57 |  |  |  | 78 |
Range of exercise prices of such options |  | $2.25 - $7.02 |  |  | $1.85 - $7.02 |  |  | $2.25- $7.02 |  |  | $1.85 - $7.02 |
The above options, which were outstanding at November 3, 2018, expire from March 19, 2020 to June 29, 2028. Shares of unvested time-based restricted stock of 30,000 at November 3, 2018 and 53,333 shares at October 28, 2017 were excluded from the computation of basic earnings per share and will continue to be excluded until such shares vest. The 30,000 shares of restricted stock outstanding at November 3, 2018 are considered issued and outstanding. Each share of restricted stock has all of the rights of a holder of the Company’s common stock, including, but not limited to, the right to vote and the right to receive dividends, which rights are forfeited if the restricted stock is forfeited.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration